Blood Clotting Factors Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

Haemophilia is a rare disorder affecting very small fraction of population across the globe. Pharmaceutical companies invest less amount on development of such drugs due to low return on investment. However, FDA has recognised this fact and has formulated favourable policy to motivate companies to invest in this area. Orphan Drug Act that applies to company operating in this area provides three special incentives i.e. 7 years exclusivity period, tax credit and waiver of prescription drug user fees. Due to such policy, the company has invested in rare disease research which has led to development of products such as Hemlibra (Emicizumab-kxwh), Adynovate and Others. Furthermore, increasing awareness regarding rare disease in developed economies such as U.S. and Canada has resulted in high number of patients receiving treatment. Owing to above mentioned factors, North America has dominated the market and it is also expected to retain position over the forecast period. Asia Pacific is expected to witness robust growth in the market due to improved ratio of patients suffering from disease and patients receiving treatment. Availability of generic products, at much lower price compared to branded product, in the market is expected to fuel growth of the market in Asia Pacific.

Low adherence to treatment among patients with Heamophilia has hindered the growth in this market. According to The National Haemophilia Foundation, about 75% of people suffering from haemophilia either don’t receive or don’t have access to complete treatment.

Key players operating in Blood clotting factors market include Shire Plc, Baxter International Inc., Grifols International SA, Roche AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, Biogen Idec, and Kedrion S.P.A.

Ask for detailed Sample of the Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1301

“The Sample consists of Table of Content, Research framework of the actual report & research methodology adopted for it”

Approval of novel drugs in key markets such as North America and Europe is expected to boost the growth in blood clotting factors market

In November 2017, the U.S. FDA approved Hemlibra (Emicizumab-kxwh) developed by Roche AG, for the treatment of Haemophilia A patient with inhibitors. This was the first approval by FDA in about 20 years to treat people with haemophilia A with inhibitors. Moreover, FDA approved Shire Plc’s Adynovate for treatment of haemophilia A patients. The drug has also been approved for use in surgical setting for both category of patients, adult and paediatric. In January 2018, the drug (Adynovate) was granted marketing authorization in European Union (EU). In EU, the drug got approval for adults and adolescents suffering from Hemophilia A. These approvals will provide the alternate option for patients suffering from haemophilia. Introduction of these drugs in market is expected to propel growth of the blood clotting factors market over the forecast period.

Blood clotting factors are proteins or enzymes that control bleeding. Blood clotting or blood coagulation is a process in which blood gets converted into solid clots at time of any wound or break down of blood vessels. Clotting can prevent death from bleeding and also restrict the entry of bacteria and viruses into the body. Haemostasis is the mechanism for blood clotting, which in controlled by a number of factors called blood clotting factors. Deficiency of these factors can cause blood clotting diseases such as haemophilia and von willebrand disease (VWD). According to Centre for disease control and prevention (CDC), 2017, around 20,000 males were suffering from Haemophilia in the U.S.

To know more about the Blood Clotting Factors Market, click the link below: https://www.coherentmarketinsights.com/ongoing-insight/blood-clotting-factors-market-1301

Segmentation of Blood Clotting Factors Market

By Product Type –

Factor VII,Factor VIII,Factor IX,Factor X,Factor XIII,Von Willebrand Factor,Anti-Inhibitor Coagulant Complex,Others,.

By Application -

Haemophilia,Haemophilia A,Haemophilia B,Von willebrand disease (VWD),Surgery,Other bleeding disorders,.

By Technology

Plasma-derived,Recombinant,

By Distribution channel -

Hospital Pharmacies,Retail Pharmacies,Online Pharmacies,.

By Geography -

North America,Europe,Asia Pacific,Latin America,Middle East,Africa,.

“Catch us at 3rd International Conference on Separation + Drying Technologies for Milk & Whey at Cologne, March 19 and 20, 2018”

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com

This release was published on openPR.